CORE--BIOCHEMISTRY AND BIOTECHNOLOGY

生物化学和生物技术设施(BBF)为Fox Chase癌症公司提供服务 中心(Fcc)调查人员使用了一组最先进的身份识别技术， 基因、多态、转录本、蛋白质和多肽的表征和利用。BBF的四个组成部分都是重要的和协同的。DMA合成提供了无错误的寡核苷酸，常规的、修饰的或荧光的探针，一夜之间，具有全面的质量控制，定量实时聚合酶链式反应提供高灵敏度和准确性的基因表达定量，并区分交替转录的调控。质谱学识别蛋白质复合体的组成，支持生化、生物物理和药物研究。 蛋白质组学揭示了全球蛋白质因疾病状态或药物治疗而发生的变化和修饰，并发现了致癌突变的次要靶点。Anthony T.Yeung博士(生物分子结构和功能)指导BBF在性能的前沿提供统一的高质量产品。这是通过主动的用户交互以及与每个学科的领导者的外部协作来实现的。53名经同行审查的调查员使用该机制，获得130笔赠款，涉及“气候变化框架公约”的所有三个司。大约95%的使用是由拥有同行审查资金的调查人员使用的。在上一次赠款期间，对DNA合成(到2003年每月700个寡核苷酸)和质谱学(2003年约有22个项目)的需求都翻了一番。此外，BBF还开发了定量实时聚合酶链式反应和蛋白质组学的新服务，因为它们是癌症研究的关键技术，分别被13名和7名研究人员使用。2003年，DNA合成公司资助了48名同行评审的研究人员，其中定量实时聚合酶链式反应14名；质谱学23名；蛋白质组学7名。BBF人员对用户的科学有深入的了解，并作为这些研究计划的高度集成工具和参与者促进他们的研究。

The Biochemistry and Biotechnology Facility (BBF) makes available to Fox Chase Cancer Center (FCCC) investigators a group of state-of-the-art technologies for the identification, characterization, and utilization of genes, polymorphisms, transcripts, proteins; and peptides. The four components of BBF are all important and synergistic. DMA Synthesis delivers error-free oligonucleotides, regular, modified, or fluorescent probes, overnight with full quality control, Quantitative Real-time PCR provides high sensitivity and accuracy gene expression quantitation and distinguishes regulation by alternate transcripts. Mass Spectrometry identifies the components of protein complexes and supports biochemical, biophysical, and drug research. Proteomics reveals the global protein changes and modifications in response to disease states or drug treatments and discovers secondary targets of cancer-causing mutations. Anthony T. Yeung, Ph.D., (Biomolecular Structure and Function) directs BBF to provide uniformly high quality products at the cutting edge of performance. This is accomplished by proactive user interactions, and external collaborations with the leaders in each discipline. The Facility is used by 53 peer-reviewed investigators with 130 grants involving all three FCCC Divisions. About 95% of its use is by investigators with peer-reviewed funding. During the last grant period, demands on DNA synthesis (700 oligonucleotides per month by 2003) and Mass Spectrometry (about 22 projects in 2003) have both doubled. In addition, new services of Quantitative Real-time PCR and Proteomics have been developed in BBF because they are critical technologies for cancer research and are used by 13 and 7 investigators, respectively. In 2003, DNA Synthesis has contributed to 48 peer-reviewed, funded investigators, Quantitative Real-time PCR, 14; Mass Spectrometry, 23; and Proteomics, 7. BBF personnel have in-depth understanding of the science of the users and facilitate their research as highly integrated tools and participants of these research programs.